Osman Kibar, founder and CEO of Samara, is a biotech entrepreneur focused on regenerative medicine, aiming to restore organ function rather than manage disease. Trained as a materials scientist, Kibar launched Samara to develop therapies that activate the body’s innate repair mechanisms, starting with severe osteoarthritis. By combining developmental biology with advanced drug discovery, he has positioned the company at the frontier of tissue regeneration. Kibar’s work reflects a long-horizon approach to biotech innovation centered on curative science.

Noubar Afeyan, founder and CEO of Flagship Pioneering, is a leading biotech entrepreneur and venture creator known for inventing companies at the intersection of science and breakthrough innovation. Through Flagship, he has co-founded and incubated dozens of life-sciences companies, most notably Moderna, helping pioneer the mRNA platform that reshaped vaccine development and global public health. Trained as a chemical engineer, Afeyan combines deep scientific rigor with venture discipline, backing long-horizon technologies across biology, health, and sustainability. His work has made Flagship a cornerstone of modern biotech company creation.

Ming Hsieh, founder and executive chairman of Fulgent Genetics, built a leading precision diagnostics company by applying advanced automation, data systems, and scalable lab infrastructure to genetic testing. After decades as a successful entrepreneur in aerospace simulation software, Hsieh founded Fulgent in 2011 and guided it from a startup into a publicly traded genomics platform offering comprehensive clinical and diagnostic testing. During the COVID-19 pandemic, Fulgent rapidly scaled nationwide testing capacity, demonstrating its operational agility and cementing its position in molecular diagnostics. Known for his engineering rigor and long-term vision, Hsieh has also emerged as a major philanthropist supporting education, medical research, and STEM initiatives.

John Oyler, cofounder and chairman of BeiGene, is one of the most prominent figures in global oncology drug development, helping build a multinational biopharmaceutical company centered on innovative, accessible cancer therapies. After successful ventures in medical technology and data analytics, he launched BeiGene in 2010 with a mission to integrate world-class research with large-scale clinical operations across Asia, Europe, and the United States. Under his leadership, the company has developed breakthrough cancer drugs, secured major partnerships with industry leaders like Novartis and Amgen, and scaled into a global enterprise listed on multiple exchanges. Known for his scientist–entrepreneur mindset, Oyler has reshaped how biotech innovation and commercialization connect across continents.